Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of goserelin microspheres plus novel hormonal agents in mHSPC
ChiCTR2500109081Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of goserelin in prostate cancer (PCa), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Proportion of patients with PSA < 0.2 ng/mL within 6 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500109081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109081.